Genevant Sciences News Today

Innate Pharma (OTCMKTS:IPHYF – Get Free Report) and Gritstone bio (NASDAQ:GRTS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Valuation and Earnings This table compares Innate […]

Moderna (NASDAQ:MRNA) stock has collapsed from its all-time high. However, the company is once again on the move — in a good way. The stock is up 68% over the past six months, with partnerships around artificial intelligence (AI) and positive cancer trial data garnering investor interest. Personally, though, I’m still unconvinced that these developments make MRNA stock a buy and require more data before I make a decision. For now, I remain neutral. MRNA stock has fallen significant...

(RTTNews) - Arbutus Biopharma (ABUS) issued statement regarding the claim construction ruling of the U.S. District Court for the District of Delaw...

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus arguments in a patent infringement lawsuit related to Modernas blockbuster COVID-19 vaccines. ...

(Reuters) -Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus arguments in a patent infringement lawsuit ...

Roivant's shares gained 4% in afternoon trading, while its subsidiary Arbutus rose more than 17%. In a so-called "claim construction order", U.S. District Judge Mitchell Goldberg interpreted parts of the patents in ways that strengthened Arbutus' case, rejecting Moderna's proposed definitions. The order is relevant in determining whether Moderna's vaccines are covered by Arbutus' patented technology.

Dublin, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The

The dawn of a new era for CRISPR patent strategy, multiplying mRNA patent wars, and 10x Genomics and NanoString’s cross-border spat were among the developments that defined the last 12 months

Lipid Nanoparticles IndustryIt is projected that the global lipid nanoparticles industry demand will be valued at US$ 877.8 million in 2023. The market is expected to expand at a CAGR of 14.2% between 2023 and 2033, reaching approximately US$ 3.3 billion by 2033, due to rising health concerns about dietary supplemen...